April 26, 2017 / 5:20 AM / 7 months ago

BRIEF-Kuros FY revenue up at CHF 1.06 million

April 26 (Reuters) - Kuros Biosciences AG:

* Merger successfully completed: Cytos Biotechnology and Kuros Biosurgery Holding combined their businesses to create Kuros Biosciences, a future leader in tissue repair and regeneration

* FY net loss of CHF 19.7 million ($19.86 million) versus loss CHF 5.8 million year ago

* Expects to receive CE mark certification for neuroseal in next months

* FY revenue of CHF 1.06 million versus CHF 144,000 year ago

Source text for Eikon: Further company coverage: ($1 = 0.9921 Swiss francs) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below